Skip to main content
OpenTrials
Completed

NCT Number: NCT00804531

Intra-discal Steroid Injection for MODIC I Discopathy

To assess the efficacy on pain level at 1 month and 12 months of a steroid injection in the inter-vertebral disc for patients with chronic back pain and inflammatory discopathy on magnetic resonance imaging.

Hypothesis: delivering anti-inflammatory drugs in situ may decrease back pain in patients with inflammatory discopathy

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Hôpital Cochin

Paris, 75014, France

About this study

Objective: to assess the efficacy on pain level of a steroid injection in the inter-vertebral disc for patients with chronic back pain and MODIC I discopathy on MRI

Methods: a multicenter double blind randomized control trial Setting: 3 tertiary care hospitals in France Patients: 134 patients with disabling chronic low back pain not relieved by usual recommended treatments and MODIC I (inflammatory) discopathy on MRI Intervention: Injection of 25 mg of methylprednisolone in the inter-vertebral disc during a discography (intervention group, 67 patients) or discography alone (control group, 67 patients) Outcome measures: The primary outcome measure is pain level assessed on a 11-point numeric scale (0-100) at 1 month. Success is defined as less than 40 on pain numeric scale at 1 month. Secondary outcome measures are pain level at 12 months, Disability (Quebec questionnaire), quality of life (SF-12) at 1 and 12 months, anxiety and depression (HAD), analgesics and anti-inflammatories during the last week, return to work, assessment of the disabilities at 1 and 12 months and disc inflammation (on MRI) at 12 months. Tolerance and adverse effects will be recorded.

Trial duration: 36 months(24 months for inclusion and 12 months follow-up) Follow-up visits: at 1, 3, 6, and 12 months Statistical analysis: intention to treat

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • More than 18 and less than 70 years old
  • Low back pain
  • Daily pain for at least 3 months
  • Pain level during the last 48 hours > 40 on the numeric pain scale (0-100)
  • Lack of efficacy of usual recommended treatments and of other spine steroid injections (epidural or facet joints injections)
  • Modic I discopathy on MRI
  • Intra-discal injection at least 6 months before inclusion
  • Written informed consent
  • Social security
  • Medical examination

Non inclusion criteria :

  • Pregnancy
  • Hypersensitivity to methylprednisolone or contrast
  • Local or general infection
  • Previous disc surgery less than 6 months
  • Steroid treatment
  • Previous infectious spondylodiscitis
  • Ankylosing spondylitis
  • Sciatica with neurologic defects
  • Uncontrolled psychiatric conditions
  • Inability to read or understand French language
  • Anti-vitamin K treatments
  • Severe coagulation diseases
  • Fever > 38 or sedimentation rate > 20
  • Discopathy with MODIC 1 signal on several different lumbar stages

Treatment and study plan

Visipaque - Hydrocortancyl

Drug

Visipaque 320 mg I/ml - 1 ml intra-discal route Hydrocortancyl 25 mg/ml - 1 ml intra-discal route

placebo comparator

Drug

Visipaque - 320 mg I/ml - 1 ml in intra-discal route

Primary outcomes

  1. Back pain level assessed on a 11-point numeric scale (0-100) at 1 month. Success is defined as less than 40 on pain numeric scale at 1 month

    Time frame: 1 month

Secondary outcomes

  1. pain level at 12 months

    Time frame: 12 months

  2. Disability (Quebec questionnaire)

    Time frame: 1 month and 12 months

  3. quality of life (SF-12) at 1 and 12 months

    Time frame: 1 month and 12 months

  4. anxiety and depression (HAD)

    Time frame: 1 month and 12 months

  5. disc inflammation (on MRI) at 12 month

    Time frame: 12 months

  6. analgesics and anti-inflammatories during the last week

    Time frame: 1 month and 12 months

  7. return to work

    Time frame: 1 month and 12 months

  8. Assessment of the disabilities (scale of 6 classes)

    Time frame: 1 month and 12 months

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • URC-CIC Paris Descartes Necker Cochin

Registry information

Official study title

Intra-discal Steroid Injection for MODIC I Discopathy: A Randomized Control Trial

Acronym: PREDID

Important dates

Study start
2009
Primary completion
2015
Study completion
2015
First posted
Dec 9, 2008
Registry last updated
Sep 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.